GU Cast | Urology Podcast (Professor Declan Murphy & Dr Renu Eapen)

GU Cast is back after our summer break in Melbourne, with a cracking episode focussing on pelvic lymph node dissection in prostate cancer. Pelvic lymph node dissection (PLND) is a perennially contentious topic in urology, and we were delighted today to welcome Dr Karim Touijer, Attending Surgeon at Memorial Sloan Kettering in New York, to discuss the randomised controlled trial which he and his colleagues published recently. This paper was highlighted as "Paper of the Year" by European Urology Oncology - congratulations to Dr Touijer and colleagues! A huge trial, with about 1500 men being randomised to undergo limited or extended PLND, to determine if a more extended dissection improved biochemical recurrence-free survival.
We were also delighted to welcome Dr Wouter "Wally" Everaerts to discuss this topic. Wally is Consultant Urologist and Program Director at KU Leuven, one of Europe's top prostate cancer centres, with huge expertise in PLND. Wally is a Melbourne alumnus and it was great have him on GU Cast.
We enjoyed talking surgery in depth today - more surgically oriented discussions coming this year!

Watch the Youtube version here

Links:
Eur Urol Oncol paper
Dr Karim Touijer Twitter
Dr Wouter Everaerts Twitter

This week saw the opening of another multi-centre randomised trial of PSMA PET/CT in Australia. And it's a cracker! PRIMARY 2 follows on from the success of the PRIMARY trial published in European Urology recently (see links below). It is aimed at men with some clinical suspicion of prostate cancer, but no definite lesion on MRI (PIRADS 2/3). Is it ok to just to monitor these men (a la PRECISION)? Many will still undergo prostate biopsy if there is a high clinical suspicion (such as high PSA density, palpable lesion, strong family history), but could PSMA play a role in reducing the number of men undergoing biopsy, and provide a target in some cases?
We are joined by trial co-PIs Professor Louise Emmett and Professor Michael Hofman,  Nuclear Medicine Fellow Dr James Buteau and Urology lead A/Professor Daniel Moon, to discuss the innovative trial design. It will recruit 600 men from multiple sites across Australia.  We're excited about this one!
Plus a new segment! Urology Registrar Dr Aoife McVey is dropping in to tell us "what caught my eye on twitter" this week. Welcome Aoife!And PROStic nurse consultant Liz Medhurst gives a plug for the upcoming ProsTIC Preceptorship.
Regular co-host Dr Renu Eapen is at ASCO GU so Daniel Moon kindly stepped in to help Declan Murphy today

Also posted on YouTube 

Links:
PRIMARY trial European Urology 2021
PRIMARY 1 podcast
ProsTIC Preceptorship
Aoife's favourite tweet this week

2022 finally sees some return to normality in the world of GU conferences. Hooray!
Today we chat with the leaders of two of our absolute favourite meetings - the European Association of Urology (EAU) Annual Meeting, and the Advanced Prostate Cancer Consensus Conference (APCCC). We are joined from Germany by Chair of the EAU Scientific Committee Professor Peter Albers, and from Switzerland by President of the APCCC, Professor Silke Gillessen. And we were pleased to say there is a lot to look forward to!!! These meetings are back to their usual in-person format, but as you will hear, they have also embraced some lessons learned due to virtual meetings.
Usual co-host Dr Renu Eapen is still meandering back to Melbourne after ASCO GU, so Declan is joined by his new Fellow, Dr Veeru Kasivisvanathan.

Also posted on Youtube

Links:
APCCC - Lugano, 28-30 April 2022
EAU Annual Meeting - Amsterdam, 1-4 July 2022

Well the data are clear, says eminent biostatistician and research methodologist, Dr Andrew Vickers of Memorial-Sloan Kettering Cancer Centre in New York. In some well constructed recent articles, Andrew has really made us think again about the impact of  moving to MRI-directed triage and targeted biopsies, instead of "blind" systematic biopsies. Could it be that this strategy actually leads to harm, rather than the clear benefits which many assume that MRI has brought to prostate cancer diagnostics??
We are joined today by Andrew, and two household names in the world of MRI-targeted biopsies to defend the practice (which is now recommended by all major guidelines). Professor Caroline Moore, Urologist at University College London, and Dr Veeru Kasivisvanathan, Urology Fellow at Peter MacCallum Cancer Centre in Melbourne. Veeru and Caroline were first and senior authors on the landmark  PRECISION trial published in NEJM in 2018 which led to the adoption of MRI in early detection of prostate cancer.
And Dr Renu Eapen  is back from her travels and in her usual co-hosting role, along with Professor Declan Murphy. Plus Dr Aoife McVey returns to tell us what caught her eye on twitter this week. A cracking episode!

Also posted on Youtube here

Links:
Dr Andrew Vickers Twitter
Professor Caroline Moore Twitter
Dr Veeru Kasivisvanathan Twitter
Dr Aoife McVey Twitter
@Urology_tips Twitter
Dr Laura Bukavina Twitter
Andrew's recent European Urol article on the harms of MRI-targeted biopsies ($)
Renu's ASCO GU talk

Today Declan and Renu chat with two young doctors who have spent the past few weeks on the Poland-Ukraine border, helping with the refugee crisis triggered by Russia's invasion of Ukraine. Just amazing stories of desperation and tragedy, with some inspiring tales of resilience and generosity.
Dr Laura Bukavina is a Urology Fellow at Fox Chase Cancer Centre in Philadelphia, and Dr Alberto Castro is a research Fellow at Fox Chase, soon to start his urology residency. Laura is a Ukrainian and tells the story of why she got on a plane as soon as the invasion started, and headed for the Ukrainian border. Alberto joined her within a few days. Some amazing stories.
To do what you can to help, please visit Laura's gofundme page and make a donation.

GU Cast hosts are Professor Declan Murphy and Dr Renu Eapen

We also cross-posted this on YouTube including some amazing photos and videos from the border. Well worth a watch.

Links:
gofundme
Dr Laura Bukavina Twitter
Dr Alberto Castro Twitter

GU Cast moved on-site this week to the ProsTIC Preceptorship in Melbourne, a state-of-the-art meeting focusing on PSMA Theransotics, led by the PCF-funded ProsTIC Centre of Excellence at Peter MacCallum Cancer Centre. What a great meeting! In-person and virtual with on-demand available for two years (links below).
We invited international guest Dr Tom Hope, Nuclear Medicine Physician and Radiologist at the University of California San Francisco, to join us for a late-night drink in our GU Cast studio at the Sofitel in Melbourne, to have a chat about all things PSMA. Along with Australian PSMA pioneers Professor Michael Hofman (Peter MacCallum Cancer Centre) and Professor Louise Emmett (St Vincent's/Garvan in Sydney).
A truly relaxed chat about where it all began, where we are now, and where it is all going. No holds barred, very entertaining.
Hosted as ever by Dr Renu Eapen and Professor Declan Murphy.

You can also watch this podcast on YouTube and see our nice late-night set-up on Level 48 of the Sofitel in Melbourne.

Links:
ProsTIC Preceptorship
ProsTIC Twitter
Dr Tom Hope Twitter
Professor Michael Hofman Twitter
Professor Louise Emmett Twitter

Another GU Cast special from the ProsTIC Preceptorship in Melbourne. Today Dr Renu Eapen welcomes back guest co-host Associate Professor Arun Azad, Medical Oncologist at Peter MacCallum Cancer Centre, to discuss some fantastic translational work going on in his Centre based on our Lutetium PSMA experience.
We welcome three great guests to talk about their work. Dr Luc Furic is Head of Translational Prostate Cancer Research at Mac; Dr Louise Kostos is a Medical Oncologist doing a PhD looking at mechanisms of resistance with LuPSMA, and Dr Heidi Fettke is a Post-Docotoral researcher focussing on circulating tumour cells in LuPSMA patients. Plus of course co-host Dr Eapen is also doing a PhD focussing on the immunology of patients receiving LuPSA on the LuTectomy trial.

Amazing discussion about the very exciting translational opportunities which LuPSMA presents.

Also posted on YouTube if you want to see us in studio

Links
ProsTIC Preceptorship 
ProsTIC Twitter
Dr Louise Kostos Twitter

To celebrate the return of the world’s premiere prostate cancer meeting, GU Cast is very pleased to bring you the first of three special editions from the Advanced Prostate Cancer Consensus Conference 2022. GU Cast co-host Professor Declan Murphy joined other panellists and delegates in beautiful Lugano, and recorded interviews with many other speakers and attendees, and captured some fantastic footage by Lake Lugano (check out our YouTube version). In this episode, Declan chats with APCCC Convenors, Dr Silke Gillessen and Dr Aurelius Omlin, and panellists Dr Pierre Blanchard, Dr Jochen Walz, and Dr Bertrand Tombal, along with patient representative David Mathesen. Plus Dr Derya Tilki rather cheekily turns the microphone on Declan! Of course APCCC is now a hybrid meeting, so you can still register and enjoy the full presentations and discussion (link below). 

You can also watch this podcast on YouTube and enjoy some great scenery in Lugano.

Links:
APCCC Website 

Declan Murphy stops off at the world-famous Netherlands Cancer Institute (NKI) in Amsterdam for a couple of days to visit his old friend, Professor Henk van der Poel. Henk is Consultant Urologist and Chief of Urology at the NKI, and leads a fantastic team with world-renowned expertise in GU oncology. 

Declan spends a day in the operating room to watch Henk perform robotic radical prostatectomy and extended pelvic lymph node dissection using a fluorescence-guided approach to detect sentinel lymph nodes, and hears the latest about Henk’s ongoing trials in this area. 

He then spends a day engaging with some of Henk’s collaborators and PhD students, and has a sit-down chat with Henk and Dr Hilda de Barros who recently published a very nice manuscript in European Urology on PSMA radio-guided surgery.

 GU Cast also cross-posts on Youtube - check out Declan's visit to NKI here. 

Links:

Netherlands Cancer Institute
de Borras et al European Urology paper
Youtube version  

Declan continues his three part podcast from the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Imaging played a very dominant (and disruptive) role at APCCC 2022, especially PSMA PET/CT with lots of “train has left the station analogies” and a healthy amount of panellists wanting to stay on the platform! 

Today Declan speaks with four imaging experts to hear their thoughts. Nuclear Medicine physicians Professor Michael Hofman (Melbourne), Professor Stefano Fanti (Bologna) and Dr Ken Herrmann (Essen), were joined by MRI guru Professor Anwar Padhani (London). Fair to say the prostate cancer world needs help figuring out what to do with PSMA PET/CT!! 

Dr Marcus Cumberbatch, Consultant Urologist at the University of Sheffield Hospital (Sheffield), and Melbourne alumnus, gives a great perspective of his experience as a delegate at APCCC.

Finally (for this episode), Declan speaks with top prostate cancer specialists Dr Neha Vapiwala, Radiation Oncologist at the University of Pennsylvania (Philadephia), and Dr Elena Castro, Medical Oncologist at the Virgen de la Victoria University Hospital (Malaga). 

Also cross-posted including some great video on our YouTube channel.

Links:
APCCC Website 

In his third and final podcast from Lugano, Declan chats with Dr Axel Merseberger (Lubeck), Dr Jochen Walk (Marseille), Ms Jane Fisher (Melbourne), and Dr Chris Sweeney (Boston/Adelaide). Plus listen out for fantastic father and son act, Professor Joe and Oisin O'Sullivan, who played for the crowds outside the Villa Cian. 

Silke Gillessen and Aurelius Omlin were also pleased to announce the dates of the next APCCC which will take place from 25-27 April 2022 in spectacular Lugano. 

GU Cast is our regular podcast brought to you by Professor Declan Murphy and Dr Renu Eapen, Urologists at Peter MacCallum Cancer Centre in Melbourne. Available on all major podcasting platforms. Now also cross-posting on YouTube. https://gucast.buzzsprout.com/

Also cross-posted on Youtube

Links:
APCCC Website
SAGENCI 

Declan Murphy continues his sabbatical adventures in Europe by spending a few days at the famous Martini-Klinik in Hamburg. The Martini-Klinik is the world's largest radical prostatectomy centre, and is preparing to move to a new building to increase their capacity even more.
In this first part of a two-part podcast/videocast, Declan chats with Chief of Urology Professor Markus Graefen, and spends some time in the operating rooms with Markus and Professor Alexander Haese, looking at the Neurosafe frozen section technique which was developed at the Martini Klinik. Plus we discuss a new randomised trial of pelvic lymph node dissection. Part 2 follows next week.

GU Cast also cross posts on YouTube. This is a great one to watch on YouTube due to our trips to the operating rooms at Martini-Klinik

Links:
YouTube version of this episode
Martini-Klinik website 

Part 2 of Declan's visit to the Martini-Klinik in Hamburg. Today he chats with Professor Derya Tilki, Urologist and Clinician Researcher, about their ongoing  research activities, including the huge database of radical prostatectomy outcomes which now includes a staggering 35,000 patients.
Plus a fantastic trip to the operating room with Professor Tobias Maurer to perform PSMA-guided salvage pelvic lymph node dissection. Declan gets to scrub in and learn from Tobias about his huge experience in this evolving area.

Also cross-posted to our YouTube channel, featuring Declan's up close experience assisting Tobias perform PSMA radio guided surgery

GU Cast returns to one of our favourite topics - PSMA imaging and theranostics! We chat with Nuclear Medicine Physician Professor Michael Hofman, and GU Medical Oncologist, Associate Professor Arun Azad, about some PSMA highlights at the recent ASCO Annual Meeting. Michael presented the eagerly anticipated overall survival data from the TheraP trial in the oral abstract session, and discusses the findings with Arun, Renu and Declan.
They also discuss another important paper in the oral abstract session - an analysis of the quantitative parameters of PSMA PET/CT scans in the VISION study.

Also available of our Youtube channel here

Wow did this paper cause a fuss this week!! The ENACT trial was published online in JAMA Oncology last weekend and provoked a huge outcry on social media. Many people were  genuinely shocked at the study design, the conclusions, even the title of the study.
We've linked to the paper below, but in summary, this prospective multi centre study enrolled patients with with low-risk or favourable intermediate-risk prostate cancer, entirely suitable for active surveillance (ie no treatment/no side-effects), and randomised half of them to receive enzalutamide. Yes enzulautmide,  a super powerful AR pathway inhibitor that works very well in men with advanced prostate cancer. But with plenty of side-effects.
So we decided to invite study co-author, active surveillance advocate and friend of teh podcast, Dr Matt Cooperberg, to come on and help us understand the rationale. We also welcomed Dr Keith Kowalczyk, Georgetown Medical Centre, Washington DC, to help us figure it out.
What do you think? Comments welcome on our Youtube channel

Links:
ENACT paper 

USANZ ASM is back! Yey! The Urological Society of Australia & New Zealand ASM was one of the first victims of the pandemic in 2020, and has finally returned, albeit delayed from its usual Feb/March slot. We caught up with a bunch of local and international delegates on the Gold Coast to talk about their scientific and social highlights. Enjoy!

Also cross posted on Youtube, well worth a watch!

Our website 

Declan and Renu bring you the first of their two part #EAU22 conference highlights from Amsterdam. How great to have the EAU back in person! We catch up with lots of old friends and bring you top scientific highlights. Guests on this episode include Jim Catto, Peter Black, Tim O'Brien, Eva Comperat, plus some fun on EAU TV with Chris Sweeney and Alberto Briganti.

Also on YouTube here 

Our website GU Cast

Part 2 of our #EAU22 highlights from Amsterdam features chats with EAU Guidelines Chair Professor Maria Ribal, the inimitable Associate Professor David Bouchier-Hayes, and a roving report from Dr Sophie Rintoul-Hoad as she sails around Amsterdam's canals. Plus some live reporting from the GU Cast reception at the Hoopman Pub in Amsterdam with Dr Alastair Lamb, Dr Marcus Cumberbatch, Dr Ben Challacombe, and a trio of colorectal surgeons who just love urology. Check out everyone wearing their GU Cast merch!
And we also cross-post Dr Matt Cooperberg's UroToday interview with Declan and Renu on the LuTectomy study. Jam packed.

Best appreciated on Youtube here 

GU Cast is pleased to cross-post another of these excellent ProsTIC PSMA theranostics webinars in collaboration with the Priotate Cancer Foundation's Global Knowledge Exchange programs. This webinar focuses on the new era of PSMA theranostics post-FDA approval.
This webinar is co-hosted by Professor Michael Hofman, Nuclear Medicine Physician and Director of ProsTIC at Peter MacCallum Cancer Centre in Melbourne, and GU Cast's own Professor Declan Murphy, with comments from the PCFs Dr Howard Soule and Dr Andrea Miyahira.  Special guest presenters include Professor Silke Gillessen, Professor Ken Herrmann, and Dr Louise Kostos and Dr James Buteau.

For all the slides and visual bits, enjoy on Youtube here 

It's been two and half years since we posted our first GU Cast and it's been fun! We are so grateful to all our listeners and viewers for supporting us, sending us great comments, and getting involved in the conversation. GU Oncology is such a fast-moving world, and we have really enjoyed posting content to keep ourselves and our audiences up to date.
We also have some exciting plans to develop the podcast and we thought we should share these with you. Tune in to this short episode to hear more! 

Better enjoyed on YouTube

Declan and Renu

Links:
New GU Cast website 

International speaker tours are back! And this week we had two fantastic GU oncology experts visiting Australia to do a lecture tour on hot topics in metastatic prostate cancer.  So of course we invited them to attend our multidisciplinary team meeting at Peter MacCallum Cancer Centre, then pop upstairs to teh Gu Cast studio.
Dr Tian Zhang from UT Southwestern in Dallas, and Dr Rahul Aggarwal from UCSF, are both prolific medical oncologists with a huge amount of expertise in prostate cancer. We asked them to highlight three key areas in each of metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer, to avoid us having to wade through teh endless stream of data in these fast-moving areas.
What areas did they chose to highlight?? Well have a listen!

Also posted on YouTube

It wasn't that long ago that we would have scoffed at the idea of using radiation therapy to treat primary kidney cancer. Not any more!! We are joined by two top experts in kidney cancer, and leaders of ongoing research in this field, to discuss the expanding role for radiation therapy in managing primary renal cancer.
Dr Rana McKay, GU Medical Oncologist at the University of California, San Diego, and Associate Professor Shankar Siva, Radiation Oncologist at Peter MacCallum Cancer Centre in Melbourne, take us through the relatively recent history of radiation for renal cancer and highlight some ongoing trials in this area. A fantastic overview for anyone interested in renal cancer.
Plus our intrepid social media watcher, Dr Aoife McVey, pops in to tell us what has caught her eye on Twitter this week.

You can watch us broadcasting from our studio here on Youtube.

Links:
Twitter - Dr Rana McKay
Twitter - A/Prof Shankar Siva
Twitter - Dr Aoife McVey
Twitter - CheatUrology
Twitter - GoumasUrologia

https://urologycheatsheets.org/ 

It's pretty shocking how many prostate cancers went missing during COVID, especially in Melbourne which experienced the most prolonged lockdown in the world. The data is still being cleaned but it is estimated that up to 3000 men who would have been expected to be diagnosed with prostate cancer over the past 2.5 years, have not yet been diagnosed.
It is prostate cancer awareness month in Australia, so a good time to chat with some experts to better understand the issue of the missing cancers. Plus we hear of some worrying examples.
Declan and Renu are joined by Alan White, well known patient advocate, Anne Savage, Chief Executive Director of the Prostate Cancer Foundation of Australia, and Professor Grant McArthur, Chair of the Victorian COVID Cancer Network, whose group have been looking at this data in real-time since the start of COVID. Grant is also a prostate cancer survivor himself.

Also posted on  Youtube

Links:
PCFA
The Prostate Zone
Peter Mac story on missing diagnoses
VCCC Alliance 

A great episode focussing on two aspects of bladder cancer. Bladder preservation for muscle-invasive cancer is in the limelight again following the recent update of the landmark BC2001 trial. We chat with bladder cancer gurus Dr Neha Vapiwala, Radiation Oncologist at the University of Pennsylvania, Dr Ashish Kamat, Urologist at MD Anderson Cancer Centre, and Dr Nathan Lawrentschuk, Urologist at Peter MacCallum Cancer Centre and the Royal Melbourne Hospital. Everything you need to know!
Plus a chat about the fascinating Bladder Path study presented by Dr Nick James at ESMO22, challenging the role of TURBT in managing bladder cancer. Spicy!
And of course, Dr Aoife McVey pops up with her Twitti-Leaks section (yes she has given it a name)!

Even more enjoyable on YouTube 

"Prostate Specific" Membrane Antigen PET/CT - now also available to stage kidney cancer! We seriously need a name change here. Already we know that PSMA PET/CT shows a lot more than the prostate/prostate cancer, but could it have utility in staging renal cancer?? We've certainly had a lot of off-trial experience of this at Peter MacCallum Cancer Centre since 2014, and we know see data  in Eur Urol Open Science to describe this experience.
We are joined by senior author Associate Professor Shankar Siva, radiation oncologist at Peter MacCallum Cancer Centre, Dr Rana McKay, GU medical oncologist at the University of California, San Diego, who has an interest in FOLH1 expression in renal cancer, and Peter Mac nuclear medicine physician Professor Michael Hofman, to discuss PSMA and renal cancer.

Check out this episode on Youtube

Links:
Prof Siva's paper in Eur Urol Open Science

OK this episode of GU Cast is essential listening for anyone who has anything to do with androgen deprivation therapy (ADT), or "hormone therapy", for men with advanced prostate cancer. Whether you are a prescriber (especially if you are a prescriber), nurse or allied health professional, patient, loved one, industry representative, or researcher - this is one not to miss.
Tim Baker is an award-winning author, journalist and storyteller specialising in surfing history and culture. At the age of 50, he was diagnosed with metastatic prostate cancer (PSA 120 and bone metastases), and has been on intermittent ADT for the past seven years. Thankfully his cancer is well controlled, but the story of his experience is a sobering insight into the devastating impact of ADT, especially in a younger man. But his self-directed strategy of MEDS (Meditation; Exercise; Diet; Sleep), is an inspiring insight into under-utilised mechanisms to make life on ADT more tolerable.
Although he is a believer in medical science and is grateful for the expertise of the specialists who have looked after him., Tim's description of his initial diagnosis and management is uncomfortable listening for those of us who prescribe a lot of ADT.
We all need to do more to support our patients in these situations, and Tim's story certainly gives plenty of food for thought. Meditation? Surf classes? Psychedelic-assisted therapy? It's all in here!
Declan and Renu loved this book. It's a great gift for anyone involved in the hormone therapy arena - why don't you pick up a copy or give it as a present for Christmas?! Available in all the usual places.

GU Cast is even better on Youtube

Links:
Tim Baker's website
Tim Baker twitter
Meditation video
Yoga Nidra video
Prostate Cancer Foundation of Australia

A GU Cast Ireland Special! Declan recently travelled to the Annual Meeting of the Irish Society of Urology and posted this GU cast special from Killashee House in County Kildare. Apologies in advance for him wallowing in his Irishness! 

Declan catches up with Urologists David Bouchier-Hayes, Eva Bolton, Catherine Dowling, and Richie Power, to chat about everything from Terence Millen and Peter Freyer to how the Irish are inspiring young women to do urology. Plus we hear about the late Dan Kelly, a legendary Irish urologist who passed away recently. 

Our Youtube version features some great scenes from beautiful Killashee House

Congratulations to ISU President Kiaran O’Malley and his organising committee. 

Enjoy! 

Links:

Irish Society of Urology

Is grade group 1 (Gleason 6 in old money) really prostate cancer? Wouldn't life be a little easier for patients (and the rest of the world) if we could somehow remove the label "cancer" from this relatively indolent condition??
Well this decade-old discussion seems to have developed a lot of momentum in the past year, driven by urologists like Dr Scott Eggener (University of Chicago) and Dr Matt Cooperberg (University of California San Francisco), who with others have written some nice articles to argue the case for "re-branding" grade group 1 as a non-cancer. This would certainly deal with the lingering issue of over-treatment of low-risk prostate cancer which persists to a variable extent around the world.
Alas, it's not so simple. Expert GU pathologists like Dr Eva Comperat (University of Vienna) point out that this is cancer. Period. If the clinical community have an issue with over-treatment, then we should deal with this another ways, rather than ask for the impossible.
Today we thrash this out with Scott, Matt and Eva. A great listen/watch. And maybe a way forward...

Even better on our YouTube channel

The annual Prostate Cancer Foundation (PCF) Retreat is in its 29th year, and is the showpiece event of the PCF's incredible research program. Each year, PCF investigators from around the world gather in California to share their work and interact together. Fair to say it has developed a legendary status among the prostate cancer community across the globe.
GU Cast's Dr Renu Eapen has recently received a PCF Young Investigator Award to support her PhD into immunological aspects of prostate cancer in patients receiving Lu-PSMA on the LuTectomy trial, so she was excited to travel to Carlsbad (CA) to attend this year's PCF Retreat. She joined up with fellow Young Investigator Dr Edmond Kwan to bring us a few highlights from this year's meeting. Lots of familiar faces in there! Watch out for Felix Feng, Misha Beltran, Howard Soule, Andrea Miyahira, Todd Morgan, Chuck Ryan, Tyler Seibert, Alicia Morgans, Neeraj Agarwal, Gina Carithers and many more.

Even better on our Youtube channel

Links:
The PCF
Urotoday 

So if you haven't seen all the fuss about ChatGPT on social media in the past two weeks, then imagine this. You have to write a 500 word introduction to an article on adjuvant therapy following renal cancer surgery, you are a week past deadline and  you have writer's block. Or it's your thankless task to organise next year's on-call roster for your Department. Or your year 11 son has asked you to explain Max Planck’s Determination of the Avogadro Constant.
Well fear not, ChatGPT is here to save the day!! Just type in the request, and this quite remarkable AI tool will spew out the answer, with quite incredible literacy (including citations), and even empathy and humour. Just sensational. It will even write code to help you build that app you always wanted but had no idea how to program. Need a patient-friendly explanation of a new trial? Or maybe a big grant application. Just type in your request, and hey presto, ChatGPT does the rest. In seconds. For free!
Today we have invited some great guests to discuss this topic. Dr Anobel Odisho (UCSF) has been all over this for years, and has posted some fantastic tweets about this. Communications guru Todd Morgan (University of Michigan) and urology trainee Jonathan O'Brien (who is doing research on AI in penile cancer) pitch in with their thoughts. And we are also joined by Liam Mannix, National Science Reporter with leading Australian broadsheets The Age and Sydney Morning Herald.

Even better on our Youtube channel

Links:
ChatGPT through Open AI
Liam Mannix's article in The Age
David Canes excellent sub-stack overview

Twitter links
Anobel Odisho
Todd Morgan
Liam Mannix
Jonathan O'Brien
David Canes

With approvals and reimbursement increasing all the time for the use of AR pathway inhibitors (ARPIs) in metastatic hormone-sensitive prostate cancer (mHSPC), we chat today about how front-line clinicians need to make sure we are making the most of these opportunities for our patients. Urologists in particular are the clinicians who most frequently diagnose men with metastatic prostate cancer, and who therefore need to be aware of the changing opportunities to improve outcomes for our patients.
Today in this Themed Episode supported by our Gold Partner, Janssen, we chat with Professor Fred Saad, Chair and Professor of Urology at the University of Montreal, who says it is "unethical to treat newly diagnosed metastatic prostate cancer with ADT alone"! We are also joined by Dr Ciara Conduit, Medical Oncologist at Peter MacCallum Cancer Centre, who helps us understand management options for these patients.

Also available as a video podcast on our YouTube channel 

Stereotactic Ablative Body Radiotherapy (SABR) has been a great tool for managing low volume metastatic prostate cancer for a few years now. One or two visits to the radiation centre, highly targeted, minimal side-effects. So could it be used to treat the primary prostate cancer itself with similar success?
Today we have top SABR experts Dr Alison Tree (Royal Marsden Hospital, London), and Associate Professor Shankar SIva (Peter Mac, Melbourne) in the GU Cast studio, and Dr Gerard Morton on Zoom from Sunnybrook Cancer Centre in Toronto. Alison talks through the most recent update from the PACE-B study and we ask which technology is best for prostate cancer.

Full video podcast available on our YouTube channel 

Two cracking bladder cancer studies to discuss on GU Cast today (in our brand new GU Cast studio)! We are joined by Dr Sia Daneshmand, Urologist and Director of Urologic Oncology at the University of Southern California, who presented the headline-making Tar-200/SunRIse-1 study at the recent Annual Meeting of the American Urological Association. Not sure what a urological pretzel is and how it can help patients with high-grade non-muscle-invasive bladder cancer? Sia explains all! 

He was also an investigator on the SWOG 1011 trial presented at the ASCO Annual Meeting recently by Dr Seth Lerner. A practice-changing randomised trial of standard vs extended pelvic lymph node dissection for patents with invasive bladder cancer. 

These are very significant papers and we really enjoyed having Sia on GU Cast to discuss. 

Even better on YouTube when you can check out our new studio!

Dr Sima Porten from the University of California San Francisco (UCSF), was in Melbourne this week for the ANZUP Annual Scientific Meeting (more from that in an upcoming episode), so she popped into the GU Cast studio to chat with Renu and Declan. Renu of course spent a year with Sima and colleagues doing Fellowship training in GU Oncology so she was very happy to have her good friend and mentor in town.
Sima is a very highly regarded expert in bladder cancer and delivered some great talks on this topic to the ANZUP ASM this week. We chat with her about strategies to help patients avoid cystectomy (bladder removal) despite refractory high-grade bladder cancer. We also chat about avoiding cystectomy in muscle-invasive bladder cancer, and her thoughts on open vs robotic surgery from her perspective as a very high-volume bladder cancer surgeon.

Even better when watched on YouTube 

This is for hardcore PSMA aficionados!! This is the 7th of our ProsTIC/Prostate Cancer Foundation Global Webinars focussing on all things PSMA theranostics (you can find the rest in our back catalogue stretching back to April 2020). We peek into theranostics beyond what we currently have with beta-emitters like LuPSMA, into the tantalising world of alpha-PSMA theranostics.
Multidisciplinary researchers from the PCF-funded TACTICAL project give a sneak into current and future work. Hear from Memorial Sloan Kettering Cancer Center experts Prof Mike Morris, Dr Lisa Bodei and Dr Jason Lewis about very exciting developments in DLL3 imaging and theranostics in neuroendocrine prostate cancer;  Dr Marwa Rahimi (Radiochemist at Peter MacCallum Cancer Centre) and David Pattison (Nuclear Medicine Physician, Royal Brisbane Hospital), overview Lead-212 targeted alpha therapy; and Dr Megan Crumbaker (Medical Oncologist (St Vincent's Hoapital, Sydney) who discusses Actinium-225 clinical data. Plus Dr James Buteau (Nuclear Medicine Physician, Peter Mac) on the Q&A
Co-hosted by Declan Murphy and Michael Hofman from the GU Cast studio in Melbourne. along with Dr Howard Soule and Dr Andrea Miyahira from the PCF in California. Even better as a video podcast 

This, our 100th episode, is a very special GU Cast, in which we remember the devastating 2011 Christchurch earthquake, which hit just as the Urological Society of Australia & New Zealand (USANZ) Annual Scientific Meeting (ASM) was kicking off in the city. 185 people lost their lives with many thousands injured, and with huge devastation across the region. Declan returned to Christchurch recently to put together this special episode, which includes some of his original footage from the time of the earthquake.
The highlight of this episode is a full replay of this year's Harry Harris Oration, delivered in February 2023 at the USANZ ASM in Melbourne. Dr Samuel "Harry" Harris, was one of the founding fathers of USANZ, and this annual oration in his name at the opening ceremony of our ASM is the most prestigious in the USANZ calendar. We invited the four inaugural recipients of the Christchurch Medal,
Urologists Dr Stephen Mark (Christchurch), Dr Lydia Johns-Putra (Ballarat), Dr Stuart Phillip (Brisbane), and Dr Julian Shah (London), to deliver the Harry Harris Oration by remembering Christchurch.  These four individuals were recognised for acts of extraordinary bravery in the rubble of Christchurch, risking their own lives to help victims in the immediate aftermath of the disaster. In this Harry Harris Oration, the Christchurch Medallists transport us back to the events of that fateful day, and reflect on what it means today. For those of us who were there, this was a very emotional and sombre occasion; for those who were not, this will be a chance to understand why the Christchurch Earthquake is such an important event in the history of our community.
We are very proud of this special GU Cast. We do hope that it means something to our audience around the world.

This episode best appreciated on YouTube

Declan and Renu as you haven't seen them before! They leave their cosy  podcast studio to do battle at the Australia & New Zealand Urogenital & Prostate Trials Group (ANZUP) Annual Scientific Meeting! The battleground is renal cancer, with Renu arguing in favour of adjuvant immunotherapy, and Declan arguing against. No holds barred. Who wins??! Tune in to find out.
Plus we chat with some of the ANZUP ASM international faculty including Alex Wyatt, Lauren Buffart, Ananya Choudhury, Andrea Apolo and Darren Feldman.
Congratulations to ASM Convenors Ben Tran and Renu Eapen, their Scientific Meeting and all at ANZUP  for putting on a terrific meeting. Thanks to ANZUP for allowing us to use footage from the debate, and to debate sponsors MSD who are also GU Cast Silver Partners. 

This episode best enjoyed on YouTube

Major scientific journals only change their Editor-in-Chief every 8-10 years so it's quite a big deal when it happens! Today we chat with Professor Alberto Briganti, incoming Editor-in-Chief of European Urology,  the world's highest ranked urology journal, and with Professor Morgan Roupret, incoming Editor-in-Chief of European Urology Oncology.
Why has everybody's impact factor dropped this year? What are their grand plans for their respective journals? How can we get our research noticed? Hear all the answers with Declan and Renu in this episode of GU Cast.
Plus Aoife McVey returns to tell us what caught her eye on social media this week.

Even better as a video podcast on our YouTube channel 

Here's a quick plug for another podcast that GU Cast is very happy to support!
Launching in September 2023, the European Urology Podcast is a new monthly podcast to accompany the world's highest ranked urology journal, European Urology. Co-hosted by Professor Declan Murphy in Melbourne and Dr Joyce Baard in Amsterdam, the European Urology Podcast will highlight key papers and feature interviews with authors, editors and special guests. It will be produced by the team behind GU Cast.
Learn more in this short trailer and subscribe on your favourite podcast platform to get the latest content. Just search European Urology Podcast.
Also available as a full video podcast on the European Urology YouTube channel 

What is a rectal spacer and do they help reduce side-effects from prostate radiation??! That's today's topic on GU Cast. Renu caught up with rectal spacer enthusiasts Professor Peter Orio (Dana Farber Cancer Institute) and Associate Professor Shankar Siva (Peter MacCallum Cancer Centre) in downtown Melbourne this week to learn all about this topic.
Thanks to our friends at Icon Cancer Centre who supported Peter's educational tour to Australia this week.
Also watch full video on YouTube
Links:
Randomised trial of Barrigel rectal spacer in JAMA Oncology 2023 https://jamanetwork.com/journals/jamaoncology/fullarticle/2801296

Is this the solution to screening for prostate cancer?? Don't bother with a PSA test and instead screen using a 10 minute MRI scan??! Re-IMAGINE is a very interesting prospective study published in BMJ Oncology this week which did exactly that with some really interesting findings.
We are joined by study authors Professor Caroline Moore and Professor Shonit Punwani to discuss.

Even better on our YouTube channel

Links:
BMJ Oncology paper
Coverage in Urology Times 

The mass media were quick to pick up on two papers in JAMA Surgery last week with headlines such as "Patients have better outcomes with female surgeons", and "Should you pick the sex of your surgeon?". So what's it all about??
We chat with lead author of one of these papers. Dr Chris Wallis, Urologist at the University of Toronto, whose looked at outcomes for more than 1.2 million (!!) patients undergoing a range of surgery types, and showed that patients operated on by female surgeons had less complications and better survival. Another study from Sweden showed similar benefits in patients undergoing gallbladder surgery.
Chris tells us more. Plus Aoife McVey brings us some great social media highlights this week. 

Even better on our YouTube channel

Article Links:
Chris Wallis et al paper
Swedish study on gallbladder surgery
Guardian Newspaper article

Twitter Links:
Fun at the EUREP Meeting courtesy of Uros Milenkovoic
Kim Kardashian in an MRI scanner
Rhea Liang weighs in on ortho comments
David Canes explains bladder diverticulum 3

David Canes Youtube channel 

The European Association of Nuclear Medicine (EANM) Annual Meeting is the World's leading nuclear medicine extravaganza! Today we cross live to Professor Michael Hofman and friends to hear some of the GU highlights at this year's annual meeting in Vienna.  Michael is joined by Prof Ken Herrmann, Dr Kerry Jewell, Dr Francesco Ceci, Dr Phiilip Kuo, Dr Bastiaan Privé and Dr Wolfgang Fendler. A fantastic update from EANM in Vienna!

Even better on our YouTube channel

We hijacked our good friends Professor Boris Hadaschik (Urologist, Essen, Germany), and Associate Professor Tyler Seibert (Radiation Oncologist, University of California, San Diego), who happened to be in Melbourne this week, and diverted them into the GU Cast studio for a chat about high-risk prostate cancer. Boris and Tyler were on a speaker tour supported Janssen Pharmaceuticals, so we put together this Themed Podcast supported by Janssen (Gold Partners of GU Cast), to probe three key questions in high-risk prostate cancer in 2023:
1. What is the role of PSMA PET/CT in initial staging?
2. If the PSMA PET/CT is N0, can we avoid pelvic lymph node dissection?
3. What is the optimal radiotherpay strategy for high-risk prostate cancer in 2023?
Superb multidisciplinary chat with two great experts. Thanks to Janssen for their support for this Themed Episode of GU Cast.

Even better on our YouTube channel

Twitter links:
Boris Hadaschik
Tyler Seibert 

One of our most popular episodes in 2022 was "Patting the Hormone Therapy Shark" with author, surfer and prostate cancer survivor, Tim Baker. And a lot has happened in the 12 months since so we invited Tim back for a follow-up chat in this Themed Podcast supported by our GU Cast Gold Partners, Mundipharma.
Tim's inspiring approach to managing the side-effects of androgen deprivation therapy are well worth knowing for anyone involved in advanced prostate cancer including clinicians (especially clinicians!), nurses and allied health care professionals, industry, and of course patients and their loved ones. Tim runs through his "MEDS" strategy in this podcast, and also chats about other options including creative writing, the topic of his ongoing PhD.
Thanks to our friends at Mundipharma for their ongoing support for GU Cast through their Gold Partnership.

Even better on our YouTube channel

Links:
Tim's website
Previous GU Cast episode 

The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.

Even better on our YouTube channel

Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.

Funding/Support:
This investigator-initiated study was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis.

Acknowledgements:
We thank the medical, surgical, nursing, nuclear medicine, and administrative staff of all the departments at the Peter MacCallum Cancer Centre who were involved in this trial. We thank the patients who agreed to participate in the study. PSMA-617 was supplied
 by Novartis and no carrier added 177Lu by the Australian Nuclear Science and Technology Organisation (ANSTO).
We remember and thank the late Dr John Violet for his involvement including study conception and design.

Links:
LuTectomy paper in European Urology
LuTectomy Editorial 

What a great ESMO for GU Oncology!! Declan caught up with some plenary speakers in Madrid to discuss the biggest topics. PSMA theranostics with Louise Emmett (ENZA-P) and Oliver Sartor (PSMAfore); ARPIs in biochemical recurrence with Steve Freedland (EMBARK), Morgan Roupret and Boris Hadaschik. Plus the latest negative immunotherapy trials in prostate cancer with Christian Gratzke.

Even better on our YouTube channel 

Prof Fred Saad (University of Montreal) drops in to chat about the interesting condition that is non-metastatic castration-resistant prostate cancer (nmCRPC). Which men are at risk of developing metastases? When should we use an AR pathway inhibitor? Why PSMA PET/CT should NOT be used. And hear his thoughts on "dabbling" in prostate cancer!
Also joined by Professor Shankar Siva and Dr Louise Kostos from Peter MacCallum Cancer Centre. Hosted as ever by Dr Renu Eapen and Professor Declan Murphy.
Fred was on a speaker tour in Australia supported by Bayer Pharmaceuticals and this Themed Podcast is supported by Bayer, Silver Partners of GU Cast.
Update  -  we mentioned that darolutamide was the only ARPI listed for reimbursement in Australia (true at time of recording). We can update that all TGA approved ARPIs for nmCRPC are now reimbursed in Australia.

Even better on our YouTube channel

SABR supremos Piet Ost and Shankar Siva join us to discuss the management of lymph node-only recurrence following primary treatment of prostate cancer. And of course our resident PSMA PET/CT guru Michael Hofman also turned up as himself and Piet love debating the merits of PSMA!
How and when shoudl we image for biochemical recurrence? What are the limits of SABR? WHat about systemic therapy? It's all in this episode with great leaders in the field.
Recorded on site at Peter Mac on the fringe of the 2023 SABR Symposium. With your usual hosts Renu Eapen and Declan Murphy

Even better on our YouTube channel 

It has becoming a familiar refrain around the world , and is certainly good news for the prostate cancer community! This week, another androgen receptor pathway inhibitor (ARPI) became reimbursed for men with hormone-sensitive metastatic prostate cancer (mHSPC) in Australia. Darolutamide is already available for men with non-metastatic castration-resistant prostate cancer, and is now also available for men with mHSPC in combination with androgen deprivation therapy and chemotherapy. Therefore we continue on our mission at GU Cast to educate ourselves about the use of ARPIs in mHSPC. And yes, even simple urologists like us can get up to speed with these drugs!
Declan and Renu are joined by fellow Urologist Associate Professor Joseph Ischia, one of our favourite prostate cancer experts. And a great podcaster himself! Check out the back catalogue of "Talking Urology" using the links below.
Plus what is a "jiffy stent"??? \
This Themed Podcast is supported by Bayer, Silver Partners of GU Cast.

Even better on our YouTube channel

Link:
 https://www.talkingurology.com.au/

Dr Ashish Kamat (MD Anderson Cancer Centre, Houston),  joins Declan and Renu to discuss a very nice paper recently published in European Urology Oncology overviewsing the role of lymph node dissection (LND) in GU oncology. Really nice piece of work led by Dr Amanda Myers along with a bunch of well known names in urologic oncology. A very succinct summary of LND in bladder, upper tract urothelial, renal, prostate, penile and testicular cancer. Check out the link below to find the full paper

Even better on our YouTube channel

Links
Myers et al paper 

Our final podcast of 2023 and it's a big one!! Huge festive giveaway with three fully funded GU Cast travel awards to attend the APCCC in Lugano (April 2024) up for grabs.  Alastair Lamb zooms in from Oxford to discuss prostate cancer spatial transcriptomics.  Kiaran O'Malley (Mater Hospital, Dublin) drops into studio for a festive drink, and GU Cast Partnership & Content Manager Katie Wendt also pops in to say hi.
That's it for 2023! Declan and Renu wish all our listeners and viewers a very Merry Christmas and a Happy New Year. We'll be back early in 2024.
This episode very enjoyable on on our YouTube channel

Links:
More details on GU Cast APCCC Travel Awards
APCCC website
More from Alastair and colleagues on spatial transcriptomics in this nice explainer https://www.youtube.com/watch?v=YdzF0-PFXhc

A truly great Christmas tradition is when Toni Choueiri and his merry band of GU Oncology Fellows at Dana Farber, drop their list of the Top 10 GU Oncology papers of the year. And true to form, Toni's tweet on Christmas Day contains an immaculate list of GU highlights of 2023. A great mixture of tumour types, some brave choices with a Phase 1 study and a negative trial in there. And all the details beautifully summarised in their twitter thread (link below).  And as ever, Declan and Renu were delighted to welcome Toni back to GU Cast to further disseminate this great list and discuss highlights and controversies.

Even better on our YouTube channel

Links:
Toni's tweet with Top 10 GU Onc papers of 2023 

A quick message from Renu and Declan about our huge travel award giveaway to start the new year! Closing date Monday 15th Jan 2024
Full details on https://www.gucast.org/

A perennial topic on GU Cast!! But today we welcome a couple of very useful papers in European Urology Oncology which help us understand how PSMA PET/CT can help patient selection for pelvic lymph node dissection in prostate cancer. We are joined by Dr Giorgio Gandaglia from San Raffaele Hospital in Milano to discuss these two papers (links below).
We also hear about Declan's recent trip to San Raffaele as Visiting Professor, and he sits down for a wide-ranging chat with professor Francesco Monitorsi, Director & Professor of Urology at San Raffaele.

Even better on our YouTube channel

Links:
Can PSMA reduce PLND? A systematic review

Optimal use of PSMA to select patients for PLND. Updated validation of the Briganti and MSKCC nomograms

We reveal the three winners of our APCCC Travel Awards 2024! These three trainees will be heading off to Lugano for the world's best prostate cancer meeting which takes place from 25-27 April on the shores of Lake Lugano.

A must listen (actually a must WATCH!!) episode of GU Cast if you have any experience with the side-effects of treatment of prostate cancer. Whether you are a patient or loved one, or a surgeon/radiation oncologist/medical oncologist, or a nurse or allied health professional - then this is for you.
Declan and Renu chat about "A Touchy Subject" with the wonderful Victoria Cullen.

This one much better enjoyed on our YouTube channel!

Links:
A Touchy Subject 

For all you enthusiasts of PSMA theranostics, we bring you another one of our fabulous ProsTIC/Prostate Cancer Foundation Global Webinars with some of the best minds in the business. This is the eighth of our collaborative webinars over the past four years and the focus today is bringing lutetium PSMA earlier in prostate cancer.

Two keynote lectures from Dr Oliver Sartor (Mayo Clinic) and Professor Louise Emmett (St Vincent's. Sydney)set the scene, focusing on brand-new data from the PSMAfore  and Enza-P trials. We have an Asia-Pacific focus with a superb range of multidisciplinary panellists from across the region.

Co-Hosted by GU Cast’s own Dr Renu Eapen with Professor Michael Hofman from ProsTIC/Peter MacCallum Cancer Centre. They are joined in studio by friends of the podcast Dr Louise Kostos and Dr James Buteau.

Even better on our YouTube channel where you can see the presentations

Renu caught up with lots of experts and friends at ASCO GU in San Francisco recently and brings you all the highlights. Hear from Toni Choueiri, Matt Cooperberg (on that debate on renaming low-grade prostate cancer), Todd Morgan, Neha Vapiwala, Morgan Roupret, Sophia Kamran, Morgan Roupret, Sam Washington, plus a great chat with Tyler Seibert while they were out for an early morning run around beautiful San Francisco.
Even better on our YouTube channel

GU Cast Conference Highlights are supported by our Gold Partner, Bayer China. 

Two of the highest profile presentations at the recent ASCO GU Meeting were the plenary presentations of the CONTACT 02 trial, and the Keynote-564 trial. Generally speaking, these were well received; indeed quite enthusiastically received in some quarters! Not however in the quarter of prolific oncology commentator and Haematologist/Oncologist & Professor of Epidemiology,  Dr Vinay Prasad! “Unethical” and “sh**ty” are just some of the terms he used to describe these in two episodes of his podcast, “Plenary Session”. Declan and Renu take Vinay to task for some of the somewhat personal attacks he makes on colleagues, but do enjoy listening to his critique, and indeed agree with many of his points! 

Even better on our YouTube channel

Links:
Plenary Session podcast on Contact 02
Plenary Session podcast on Keynote-564
Dr Vinay Prasad Twitter 

Needle through the rectum or needle through the skin?? Transrectal vs transperienal prostate biopsy is certainly a hot topic in prostate cancer, with the vast majority of men having their biopsy through the rectum rather than through the skin. It is quick, cheap and easy (for the urologist and the health system), but leaves the patient at risk of serious harm from infectious complications, at least according to historic reports.
Today Declan and Renu chat with Dr Jim Hu, Urologist at Cornell University in New York, and leader of the PREVENT trial, a randomised study of transrectal vs transperineal biopsy which has just been published in European Urology. We are also joined by Associate Professor Jeremy Grummet, Urologist at Alfred Health in Melbourne, and long-time advocate of transperineal biopsy. Did this trial finally establish transperineal as the new standard of care for men undergoing prostate biopsy?? Tune in to find out!

Even better on our YouTube channel

Links:
PREVENT trial in European Urology 

Declan and Renu bring you lots of highlights and interviews from the Urological Society of Australia & New Zealand (USANZ) Annual Scientific Meeting (ASM) which took place last week in Adelaide. Almost 1000 delegates descended on this beautiful part of the world, famous for its beaches and wineries.
Hear from Robert Nam, Paul Anderson, Nathan Lawrentschuk, Alan McNeill, Axel Merseburger, Dixon Woon, Michael Choong, Jo Cresswell, Anthony Ta, and Shane La Bianca who is Convenor of #USANZ25. 
GU Cast Conference Highlights are supported by Bayer Pharmaceuticals (China), GU Cast Conference Highlights Partner.
Even better on our YouTube channel 

Axel Merseburger (Chief and Professor of Urology, Lubeck, Germany) was in Australia recently and popped into the GU Cast studio for a chat. Axel was at the USANZ ASM recently and also on a speaker tour supported by Janssen Pharmaceuticals, so we put together this Themed Podcast to pick his brains on high-risk prostate cancer and mHSPC in 2024.
This Themed Podcast is supported by Janssen Pharmaceuticals, Gold Partners of GU Cast. 

Even better on our YouTube channel

A big medical oncology love-in in the GU Cast studio today!! Professor Enrique Grande was visiting from MD Anderson Cancer Centre in Madrid to chat all about some of the sensational advances we have seen in metastatic bladder cancer in recent times. And we were also joined by old friend Professor Andrew Weickhardt from Austin Health in Melbourne to educate ourselves on what is an antibody drug conjugate and how does EV work. Plus lots of laughter!!

Even better on our YouTube channel. , Please do subscribe, rate and review.

Professor Neil Fleshner (University of Toronto) drops into the GU Cast studio in Melbourne for an intriguing discussion! First we cover off the underrated topic of cardiac risks in patients starting androgen deprivation therapy and how we can reduce these for the benefit of our patients. Then we talk to Neil about entrepreneurship and his journey into very successful business ventures in recent years. He has some inspiring stories and some great advice for frustrated clinicians out there!
This episode is a Themed Podcast supported by our Bronze Partners, Cipla Australia.

Even better on our YouTube channel

A new paper in the Journal of Clinical Oncology is reporting that the bowel and urinary side-effects of proton therapy (a high tech and very expensive type of radiotherapy), are no better than side-effects after standard high-quality radiotherapy (called IMRT). Quite a fuss on twitter when this paper came on line last week including from a fair few urologists, one of whom described proton therapy for prostate cancer as "a black eye for American healthcare"! (Thanks Scott!).
We chat with lead author Dr James Yu (Hartford, USA), and favourite GU Cast radiation oncologist Prof Shankar Siva to make sense of it all. And what does this mean for proton therapy in places like Australia who currently have no proton therapy facility.

Even better on our YouTube channel 

Links:
JCO paper 

The 2nd ProsTIC Preceptorship is one of the most intense fora for the discussion of PSMA theranostics anywhere in the world! A biennial meeting in Melbourne with many of the world's leading experts in the field. Not just superb practical advice about how to get your prostate cancer theranostics program to the next level, but some amazing discussions on where to next for theranostics in prostate cancer. Plus, watch out for the shenanigans at the conference dinner!
Our Conference Highlights are supported by our friends at Bayer China.
Even better on our YouTube channel 

Great fun on the shores of Lake Lugano where the hosts of three of the best
-known podcasts in GU Oncology get together for a chat! Declan and Renu from GU Cast, join with Brian and Tom from Uromigos, and Gill from Oncoalert. How did it all start? Why did it all start?! Best moments, worst moments etc. 
Tune if for a chat, and do please subscribe/like/follow all of us! Just search GU Cast/Uromigos/Oncoalert wherever you get your podcasts 

In the first of our special episodes focussing on GU Oncology in China, we are delighted to welcome our inaugural GU Cast China Editor. Professor Yao Zhu, to the GU Cast studio. Yao is a Urologist at Fudan University Shanghai Cancer Centre,  and is well known to all of us at GU Cast and Peter MacCallum Cancer Centre. As part of our Gold Partnership with Bayer Pharmaceuticals in China, Yao will help us put together some Themed Podcasts focussing on GU Oncology in China.
This first episode focuses on one of our favourite topics, metastatic hormone-sensitive prostate cancer (mHSPC). We chat with Yao and special guest, Professor Ning Zhang (Beijing Anzhen Hospital, affiliated to Capital Medical University), and learn a lot about prostate cancer in China!
Even better on our YouTube channel 

Today we have Dr Alicia Morgans, GU Medical Oncologist and Director of Survivorship at Dana Farber Cancer Institute, in the GU Cast studio for a chat. We wanted to ask Alicia to look forward and identify three big challenges  we will face in metastatic prostate cancer over the next 5-10 years. What did we come up with??!! Tune in to find out!!

Even better on our YouTube channel 

Should we remove bladder cancers piece-meal by chopping them into little pieces, or should we try and remove en bloc with a margin around the base?? This very nice randomised controlled trial from our friends in Hong Kong demonstrates that the recurrence rate is significantly lower if we use the all-too-rarely used en bloc technique. Dr Jeremy Teoh from the Chinese University Hong Kong joins us to discuss his paper just published in European Urology.
Check out the YouTube version for a video of the technique.

Also available as an audio only podcast wherever you get your podcasts

Full paper here 

For Urologists, there are not that many papers that come along where we can say - "this will almost immediately change my practice". But KEYNOTE-564 looks like one of those! A large phase III randomised trial of adjuvant pembro following nephrectomy for renal cell carcinoma in patients deemed at higher risk for recurrence. Regular listeners/viewers might remember we discussed this on GU Cast back in August 2021 when the disease-free survival endpoint was published in NEJM, and it would be fair to say we were cautious and kept saying "we need to wait for the overall survival data". Well here we are! Patients who received pembro for one year had a 38% reduced risk of death. Big news!

We are joined again by Dr Alex Kutikov, Urologist at Fox Chase Cancer Centre, who joined us on the original podcast. We are also joined by his colleague GU Medical Oncologist, Dr Matt Zibelman, who has a lot of experience in this area having been an investigator on the IMmotion 010 study. Unfortunately lead author Dr Toni Choueiri could not join us this time but he gets plenty of mentions!

This is a Themed Podcast supported by our Silver Partners, MSD, manufacturers of pembrolizomab, through an educational grant. MSD had no input into the content of this podcast.

Even better on our YouTube channel

Links:
Full NEJM paper
Previous GU Cast on K-564

Didn't get to ASCO this year?? Us neither!! But not to worry, we checked in with Dr Marty Schoen who did, and brings us all the key highlights! Marty is a GU Medical Oncologist at the St Louis Veterans Affairs Medical Centre and the University of St Louis, Missouri. He runs through a smattering of stuff that caught his eye at ASCO this year. Thanks Marty!

Also on our YouTube channel

Pelvic lymph node dissection down-graded. Systematic prostate biopsies no longer recommended. More clarity around PSMA PET/CT for staging. Surgery no longer recommended for cN1 prostate cancer. Yep the recent updates to the EAU Prostate Cancer Guidelines had a lot of important changes for the global urology community to digest. So we invited EAU Prostate Cancer Guideline Vice-Chair Derya Tilki, and Guideline Board Member Gianluca Giannarini, along with Elio Mazzone to join us for a deep dive into these major changes.  All you need to know!

Even better on our YouTube channel 

The first of two Conference Highlight specials from the Advanced Prostate Cancer Consensus Conference, held in April 2024 in Lugano. This is our very favourite prostate cancer meeting and we are thrilled to bring you these highlight podcasts. In this epsiode we chat with Silke Gillessen, Derya Tilki, Jochen Walz, Neha Vapiwala, Dingwei Ye, and the lucky trainees who won a GU Cast Travel Award to attend this year's APCCC. 

GU Cast Conference Highlights are supported by our friends at Bayer China, Gold Partners of GU Cast.

Even better on our YouTube channel 

Part 2 of our Conference Highlight specials from the Advanced Prostate Cancer Consensus Conference, held in April 2024 in Lugano. This is our very favourite prostate cancer meeting and we are thrilled to bring you these highlight podcasts. In this episode we chat with Elena Castro, Nick James, Anthony Joshua, Bertrand Tombal, Silke Gillessen, Aurelius Tomlin, Yüksel Ürün, Gill Morgan, and a gang of nuclear medicine phyicians including Michael Hofman, Louise Emmett, Tom Hope, Stefano Fanti, and Ken Herrmann.

GU Cast Conference Highlights are supported by our friends at Bayer China, Gold Partners of GU Cast.

Even better on our YouTube channel

There are patient advocates and there are patient advocates, and then there is Howard Wolinsky! We chat with the inimitable Howard, medical journalist and very long-time active surveillance patient, about his varied interests in low-risk prostate cancer and prostate cancer diagnostics. He runs a great substack called The Active Surveillor with a regular newsletter which we devour every week! l His  current interests are in the abolition of transrectal prostate biopsy and the campaign to re-name grade group 1/Gleason 6 cancer as a non-cancer. We chat about all this and more, including that unforgettable appearance he made at the ASCO GU Plenary session!

Also available on our YouTube channel

Subscribe to the Active Surveillor here 

In the second of our special episodes focussing on GU Oncology in China, we are delighted to welcome back our GU Cast China Editor. Professor Yao Zhu, who has put together this cracking episode focussing on radical prostatectomy in China. We are joined by Professor Ming Liu (Beijing Hospital, Beijing) and Professor Jiahua Pan (Ren Ji Hospital, Shanghai) to discuss everything from current practices of pelvic lymph node dissection up to tantalising details of the new surgical robots which are in clinical use in China.
This is a Themed Podcast as part of our Gold Partnership with Bayer Pharmaceuticals in China. We are very grateful to Bayer China for helping us promote GU Cast in China and supporting these Themed Episodes.

Even better on our YouTube channel

To celebrate the Paris 2024 Olympics, we bring you this special Olympics-themed episode of GU Cast - our very own Prostate Cancer Olympics! Yes we We are joined in the GU Cast studio by Dr Elena Castro, GU Medical Oncologist at Hospital 12 de Octubre in Madrid, who happened to be passing through Melbourne. And by our own A/Professor Arun Azad, GU Medical Oncologist at Peter MacCallum Cancer Centre, and one of our GU Cast Clinical Advisors.
We have three events and some great medal contenders, but who will win Gold??!! Tune in for some great discussion and debate, and some surprises and controversies along the way.

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson Pharmaceuticals.

Even better on our Youtube channel 

Renu and Declan escape winter in Melbourne to enjoy a few days of sunshine and science at the #ANZUP24 Annual Scientific Meeting on the Gold Coast. ANZUP is our fantastic GU Oncology co-operative trials group here in Australia and New Zealand and have an outstanding record in running clinical trials and supporting research and education in GU Oncology. Plus this is their 14th Annual Scientific Meeting with some outstanding National and International guests.
We catch up with Paul Nguyen, Elena Castro, Ravi Kanesvaran, Fiona McLean, Cristiane Bergerot and Co-Convenor Matt Roberts to bring you some great highlights of this year's meeting.
GU Cast Conference Highlights are supported by our Gold Partners, Bayer China.

Even better on our YouTube channel

Links:
ANZUP 

We were very happy to have world-famous kidney cancer guru Dr Rana McKay in Australia this week to do some educational events and to visit us at Peter Mac. So of course we also invited her to the GU Cast studio to pick her brains on all things kidney cancer, along with Dr Lewis Au, GU Medical Oncologist at Peter Mac. We asked them to cover three hot topics:
1. Adjuvant immunotherapy following surgery for kidney cancer
2. First line management of metastatic kidney cancer - how do we choose best options for individual patients? 
3. Future-gazing in renal cancer, including a focus on belzutifan.

Even better on our YouTube channel

Rana's visit to Australia was supported by our friends at MSD, Silver Partners of GU Cast.

Links:
Previous GU Cast on Keynote-564
Renu's new paper in Nature Reviews Urology! (mentioned in the intro) 

Today we dedicate our podcast to the memory of our colleague, Dr Brian Kelly (40), who passed away unexpectedly this week. We are devastated to lose Brian, who was a Consultant Urologist at Peter Mac and Eastern Health here in Melbourne, and one of our closest friends in the world.
Here we replay the Memorial Session which we conducted at Peter Mac this week. It features some great memories of Brian from contributors across the world; all of us shocked to lose one of the most special people in our urological community.
Our heartfelt condolences to Brian's mother Margaret, siblings Finnian, Sean and Ruth, and his son Tadhg.
Vale Brian we will miss you always x

YouTube for full video 

How often do you check PSA and testosterone in your patients on androgen deprivation therapy? Probably not often enough!! Declan caught up with friend of the podcast Professor Axel Merseburger at a conference recently to chat about this under-appreciated topic. Don't get too distracted by fancy scans and genomic testing; but do make sure you know a bit about why it matters to get testosterone (and PSA) as low as possible.

This is a Themed Podcast supported by our Gold Partners, Mundipharma. 

Even better on our YouTube channel

As if any of us need an excuse to go to beautiful Bali! Well the Urological Association of Asia (UAA) Annual Meeting takes place there from 5-8th September 2024. Renu caught up with Dr Agus Rizal Hamid recently to hear what the UAA have in store for us!

www.uaa2024.com

Testis cancer! We don't talk enough about this on GU Cast. But we are making up for it today with a cracking overview of three hot topics in testis cancer a couple of  world-leading testis cancer experts. We are joined by Rob Hamilton (Urologist, Princess Margaret Cancer Centre, Toronto), and Ben Tran (Medical Oncologist, Peter Mac, Melbourne) to discuss changes in surveillance for stage 1 seminoma, changes in the management of stage 2 seminoma (including robotic RPLND), and miRNA as a really useful biomarker. A really lively discussion on three really topical areas in testis cancers.

Even better on our YouTube channel

We recorded this one at the ANUP Annual Scientific Meeting in July 2024. You can find a full GU Cast covering the rest of the ANZUP24 highlights here 

More than 500 salvage radical prostatectomies!!! Yep it would be fair enough to describe Dr Paul Cathcart as being "experienced" in the most challenging scenario  we face as prostate cancer surgeons. Surgery for cancer recurrence in the prostate following radiotherapy or various forms of ablative therapy is never easy, and can all too often lead to issues with healing and quality of life recovery due to the impact of prior failed treatments, so we are always keen to see how we can improve outcomes. 
Paul dropped into the GU Cast studio when back in Melbourne this week, a little over ten years on from his Fellowship training here. He is a Consultant Urologist at Guy's & St Thomas' NHS Foundation Trust in London, where his main area of expertise is indeed salvage robotic radical prostatectomy. Paul shares his perspectives and tips and tricks for performing this procedure to try and give patients the best possible outcome, and also explains why he prefers the da Vinci Surgical System over the new robot kids on the block.
This is a Themed Podcast supported by our Silver Partners, Device Technologies, distributors of the da Vinci Surgical System.

Even better on our YouTube channel

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit.  We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.

This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel

Full paper in Lancet Oncology here 

The world's longest running live robotic surgery meeting took place in Bordeaux last week and Declan and Renu were there to bring you all the highlights! The 21st Meeting of the EAU Robotic Urology Section (ERUS) was their biggest ever with more than 1000 delegates watching more than 40 live surgeries from the world's top robotic surgeons. And this year includes some quite spectacular telesurgery with surgeons in Bordeaux and patients 8000km away in Beijing!! Renu takes a few new robots for a test drive, and we catch up with some of the biggest names in the business.
This is a Themed Episode supported by our Silver Partners,  Device Technologies Australia, distributors of the da Vinci Surgical System across Australia, New Zealand and South-East Asia

Even better on our YouTube channel

Penis Project is one of our favourite podcasts (and certainly popular with our patients), so we were delighted to welcome Host and Sexologist, Melissa Hadley-Barrett to join us for a chat. What is the Penis Project? Who is it for? (anyone with a penis, anyone who knows someone with a penis, or anyone who would like to have a penis apparently)! A cracking chat and we highly recommend subscribing. Just search Penis Project or browse the links below

Even better on our YouTube channel

Websites:
https://melissahadleybarrett.com   Men’s health only
https://rshealth.com.au/  All genders

SPECIAL OFFER - use the code MHB10 at the checkout on all the programs (penile rehab and erectile dysfunction and peyronies) or in the shop to get a 10% discount.
 
Facebook:
https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/
https://www.facebook.com/profile.php?id=100085146627814
 
Instagram:
https://www.instagram.com/melissahadleybarrett/
https://www.instagram.com/restorativehealth.clinic/
TikTok: @melissahadleybarrett
YouTube: Melissa Hadley Barrett
Linkedin:
https://www.linkedin.com/in/melissa-hadley-barrett/
TEDX
https://www.youtube.com/watch?v=IjHj1YTmLoA

Ask anyone which big oncology meeting gave us the best GU oncology highlights this year and the answer is easy! ESMO24 in Barcelona! Jammed full of key papers and so many highlights, Declan and Renu bring you a great overview in this GU Cast Conference Highlights from ESMO24.
Listen to discussions with investigators and key opinion leaders, interviews with delegates, a fun speed-walk through the prostate cancer poster session, and a fun morning at the OncoAlert 5K.

GU Cast Conference Highlights ares supported by our Conference Highlights Partner, Bayer China.

Even better on our YouTube channel

Today we celebrate one of our favourite clinical trials - ENZAMET! It is 10 years since ENZAMET opened and beyond its pivotal data establishing that adding enzalutamide to ADT improves survival for mHSPC patients, it continues to produce a very strong stream of high-quality findings that affect our practice today. ENZAMET also straddled an epochal era which included the advent of doectaxel upfront in mHSPC, and the introduction of PSMA PET/CT.
Today we were very happy to speak to two of the principal architects of ENZAMET; Professor Ian Davis, Chair of the ANZUP co-operative trials group, and Professor Chris Sweeney. Director of the South Australian ImmunoGENomics Cancer Institute, who told us the extraordinary story of how this trial came about, the challenges and evolutions of its rollout, and the strong tail end of translational and other research which it continues to produce. It is a great example of how investigator initiated trials run by nimble and ambitious cooperative trial groups like ANZUP can do things a little differently.

This is a Themed Podcast supported by our Gold Partners, Astellas.

Een better on our YouTube channel

Links:
ANZUP
Previous podcast from #ANZUP24 Annual Scientific Meeting
ENZAMET 2019 paper NEJM
ENZAMET 2023 paper Lancet Oncology

In the third of our special episodes focussing on GU Oncology in China, we are delighted to welcome back our GU Cast China Editor, Professor Yao Zhu, who has selected three huge prostate cancer highlights from the recent #ESMO24 meeting in Barcelona.  We are joined by Professor Shouzhen Chen (Qilu Hospital, Shandong University), and Professor Zhenhua Liu (Sichuan University, West China Hospital) to discuss PEACE-3, ARANOTE, and UpFront PSMA, and in particular to consider what these data mean to health care professionals and patients in China.
This is a Themed Podcast as part of our Gold Partnership with Bayer Pharmaceuticals in China. We are very grateful to Bayer China for helping us promote GU Cast in China and supporting these Themed Episodes.

Even better on our YouTube channel

You can also catch our recent full GU Cast Conference Highlights from #ESMO24 here 

A GU Cast Live Event!! Everything you need to know about treatment intensification in mHSPC!! Doublet vs Triplet. Who should have radiotherapy? PSMA PET/CT conundrums, e-escalation, case discussions and more. Featuring GU Cast Hosts Declan Murphy and Renu Eapen, Medical Oncologist Ben Tran, Nuclear Medicine Physician Louise Emmett, and Radiation Oncologist Amy Hayden. Plus lots of interaction from our live audience around Australia.
Watch the full webinar including presentations on our YouTube channel

This GU Cast Live Event was an interactive educational webinar supported by our Gold Partners, Mundipharma.

Learning objectives:
1. Provide an overview of the landscape of mHSPC today, with a particular focus on intensification of therapy
2. Provide an overview of the role of novel and conventional imaging in diagnosis of mHSPC, both synchronous
 and metachronous
3. To better understand options for intensification of systemic therapy in mHSPC
4. To better understand the role of radiotherapy in mHSPC

Highlights from a GU Cast Live Event! Dr Kim Chi (Medical Oncologist, Vancouver) and Dr Carmen Mir (Urologist, Valencia) joined the PROSPECT meeting in Melbourne to discuss high-risk prostate cancer and mHSPC, along with many experts from around Australia. On the eve of the meeting over dinner, Declan Murphy led a GU Cast-themed panel discussion on five hot topics in prostate cancer, featuring snippets from GU Cast over the past few months. Part 1 today features PSMA conundrums and triplet vs doublet therapy.

Even better on our YouTube channel

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson, who also support the PROSPECT meeting. 

Special thanks to David Chen for help with videography

What are we to make of this large RCT of extended vs standard pelvic lymph node dissection (PLND) for prostate cancer?? Despite it not meeting its primary endpoint of improving biochemical recurrence, the authors now report in European Urology that it does reduce the incidence of distant metastases 10 years later! Go figure!
We chat with Dr Karim Touijer (MSKCC) and try to figure it out. We ask about data dredging, p-hacking and statistical shenanigans, and how adding two minutes and two extra lymph nodes to a PLND could possibly lead to reduced metastases.
Plus guest comments from Dr John Yaxley (Brisbane). What do you think??!! Will this change practice?? Will this change guidelines? Tune in and share your thoughts!

Even better on our YouTube channel
Links:
Paper in European Urology
Previous GU Cast with Karim discussing earlier paper (Feb 2022) 

Part 2 Highlights from a GU Cast Live Event! Dr Kim Chi (Medical Oncologist, Vancouver) and Dr Carmen Mir (Urologist, Valencia) joined the PROSPECT meeting in Melbourne to discuss high-risk prostate cancer and mHSPC, along with many experts from around Australia. On the eve of the meeting over dinner, Declan Murphy led a GU Cast-themed panel discussion on five hot topics in prostate cancer, featuring snippets from GU Cast over the past few months.Part 2 today features controversies in PLND, the somewhat notorious ARPI switch control arm beloved of mCRPC trials, and teh importnt topic of de-escalation in advanced prostate cancer. Part 1 recently in your feeds included PSMA conundrums and triplet vs doublet therapy.

Even better on our YouTube channel

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson, who also support the PROSPECT meeting. 

Special thanks to David Chen for help with videography

Legendary British cyclist Sir Chris Hoy (48) recently shocked the world by announcing that he has progressive metastatic prostate cancer. His specialists have given him a 2-4 year life expectancy. The dreadful news that no prostate cancer patient wants to hear.
Today, hosts Prof Declan Murphy and Dr Renu Eapen welcome their good mates A/Prof Ben Challacombe (Guy's Hospital, London), and A/Prof Daniel Moon (Peter MacCallum Cancer Centre, Melbourne) to the GU Cast studio, and patient advocate Andrei Norris who joins on Zoom to discuss the huge publicity this has generated, and the importance of family history in assessing men's risk of prostate cancer.

This is a Themed Podcast supported by our Silver Partners, Bayer Pharmaceuticals.

Even better on our YouTube channel

Have you ever found the choice of agents in metastatic kidney cancer just a bit perplexing??! Well then this is the podcast for you! To celebrate a fantastic review paper recently published in European Urology, we chat with first author Dr Regina Barragan-Carillo (City of Hope, California), and second senior author Dr Tian Zhang (UT South-Western, Texas). The title of the paper is "First and Second-line Treatments in Metastatic Renal Cell Carcinoma", and it's about the best paper we have read on this topic, with a proper who's who in renal cancer contributing. Plus completely up to date with a literature review up to October 2024. 

Co-hosts Declan Murphy and Renu Eapen really enjoyed this one! 

This is a Themed Podcast supported by our Bronze Partner, Ipsen Pharmaceuticals.

Even better on our YouTube channel

Links:
European Urology paper (paywall) 

Our final episode of the year! And we end with a very seasonal celebration of single-port surgery and the Boxing Day Test with Australia playing India in one of the world's most famous cricket matches. We coaxed Dr Mihir Desai (University of Southern California, Los Angeles) and A/Prof Daniel Moon (Peter Mac, Melbourne) out of the Melbourne Cricket Ground and into our nearby studio at the close of play on Day 2 to talk all things single-port surgery (and cricket). Cricket-mad Mihir flew in from LA to tick off his bucket list ambition of attending a Boxing Day Test. We reminisce about the early days of single-port laparoscopy and talk about what robotic surgery does (and does not) bring to single-port surgery.
Plus we remember the day that Indy Gill met Shane Warne at the MCG ten years ago while attending a meeting here! Two legends of their games.
And to end season 5 of GU Cast, your hosts Declan Murphy and Renu Eapen thank our amazing Partners for supporting our ever expanding pool of content from GU Cast.

Even better on our YouTube channel

Links:
BJUi Blog about when Indy met Warnie 

Declan Murphy travels to Shanghai for the 14th GU Oncology Academic Meeting hosted by Fudan University Shanghai Cancer Centre, and to meet up with our GU Cast China Editor, Dr Yao Zhu. This is an excellent meeting in one of our very favourite cities, and this year Declan joins International Faculty including Dr Stephen Freedland (Los Angeles), Dr Karim Fizazi (Paris), Dr Axel Merseburger (Lubeck). and Dr Andrea Necchi (Milano) to overview the latest stories in GU Oncology. Top Chinese experts from across the country also join and the meeting includes some landmark consensus statements from multidisciplinary panels.
Today we post Part 1 of our GU Cast Conference Highlights from Shanghai including discussions with Conference Chair, Dr Dingwei Ye, Dr Karim Fizazi, Dr Peng Wu, and Dr Axel Merseburger.
Special thanks to our Conference Highlights Partner, Bayer China, who set up an amazing GU Cast studio for us in Shanghai. Thanks to Hexun and all the local Bayer team in China.

Even better on our YouTube channel